Table 8.
Effect of GlucoMedix® on glucose concentrations in alloxan-induced hyperglycemic rats
| Glucose (mg/dl) | ||||||
|---|---|---|---|---|---|---|
| Group/dose (mg/kg) | BASAL | 0days | 7days | 14days | 21days | 28days |
| Control (uninduced) | 90.3 ± 1.49 | 92.0 ± 1.63 && | 93.3 ± 2.36 && | 94.3 ± 2.43 && | 96.2 ± 2.41 && | 98.5 ± 2.36 && |
| Negative Control (induced) | 92.7 ± 4.50 | 495.7 ± 20.62 ** | 528.2 ± 20.42 ** | 545.7 ± 15.91** | 566.3 ± 12.34 ** | 579.0 ± 11.87 ** |
| Glibenclamide 10 | 90.3 ± 2.34 | 500.0 ± 17.03 ** | 287.8 ± 18.76 *& | 137.5 ± 8.78 *&& | 107.3 ± 4.55 && | 92.7 ± 1.97 && |
| GlucoMedix 250 | 90.2 ± 3.89 | 509.7 ± 13.83 ** | 482.5 ± 10.90 **&& | 448.7 ± 12.49 **& | 418.8 ± 16.10 **& | 396.5 ± 13.38 **& |
| GlucoMedix 500 | 94.3 ± 3.77 | 512.5 ± 14.63 ** | 324.2 ± 17.06 **& | 268.2 ± 15.83 *& | 207.2 ± 2.54 *&& | 177.0 ± 6.71*&& |
| GlucoMedix 1000 | 93.3 ± 3.33 | 501.5 ± 9.54 ** | 305.0 ± 8.00 **& | 216.3 ± 4.93 *&& | 146.2 ± 13.47 *&& | 102.2 ± 4.02 && |
Values are expressed as mean ± SD. n= 5. Statistical significance was * p<0.05, ** p<0.001 compared to control group (uninduced); & p<0.05, && p<0.001 compared to negative control group (induced)